<code id='BA7B8295CB'></code><style id='BA7B8295CB'></style>
    • <acronym id='BA7B8295CB'></acronym>
      <center id='BA7B8295CB'><center id='BA7B8295CB'><tfoot id='BA7B8295CB'></tfoot></center><abbr id='BA7B8295CB'><dir id='BA7B8295CB'><tfoot id='BA7B8295CB'></tfoot><noframes id='BA7B8295CB'>

    • <optgroup id='BA7B8295CB'><strike id='BA7B8295CB'><sup id='BA7B8295CB'></sup></strike><code id='BA7B8295CB'></code></optgroup>
        1. <b id='BA7B8295CB'><label id='BA7B8295CB'><select id='BA7B8295CB'><dt id='BA7B8295CB'><span id='BA7B8295CB'></span></dt></select></label></b><u id='BA7B8295CB'></u>
          <i id='BA7B8295CB'><strike id='BA7B8295CB'><tt id='BA7B8295CB'><pre id='BA7B8295CB'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:focus    Page View:3857
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In